EGFR and non-small cell lung carcinoma: Clinical findings indicate that the majority of non-small cell lung cancer (NSCLC) patients exhibit mutations in the epidermal growth factor receptor tyrosine kinase (EGFR), leading to increased EGFR activity and facilitating metastasis and progression of NSCLC (Jiang et al., 2022).